Form 8-K - Current report:
SEC Accession No. 0001104659-25-110913
Filing Date
2025-11-13
Accepted
2025-11-13 08:40:07
Documents
14
Period of Report
2025-11-12
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2530957d3_8k.htm   iXBRL 8-K 35069
2 EXHIBIT 99.1 tm2530957d3_ex99-1.htm EX-99.1 12220
6 GRAPHIC tm2530957d3_ex99-1img001.jpg GRAPHIC 18793
  Complete submission text file 0001104659-25-110913.txt   247924

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lvtx-20251112.xsd EX-101.SCH 3038
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lvtx-20251112_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lvtx-20251112_pre.xml EX-101.PRE 22374
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2530957d3_8k_htm.xml XML 3655
Mailing Address YALELAAN 62 UTRECHT Netherlands
Business Address YALELAAN 62 UTRECHT Netherlands 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40241 | Film No.: 251475619
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)